Knight TherapeuticsFRA:04K +0.81%73 PS Ratio is 1.93 as of Jul. 12, 2026, which is 42% below its 10-year median of 3.31. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.47. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Knight Therapeutics ranks better than 55.92% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Knight Therapeutics's share price is €6.20.
Knight Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €3.21. Hence, Knight Therapeutics's PS Ratio for today is 1.93.
Warning Sign:
Knight Therapeutics Inc stock PS Ratio (=1.91) is close to 3-year high of 1.93.
The historical rank and industry rank for Knight Therapeutics's PS Ratio or its related term are showing as below:
FRA:04K'
s PS Ratio Range Over the Past 10 Years
Min: 1.28 Med: 3.31 Max: 400.42
Current: 1.91
During the past 13 years, Knight Therapeutics's highest PS Ratio was 400.42. The lowest was 1.28. And the median was 3.31.
FRA:04K's PS Ratio is ranked better than 55.92% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs FRA:04K: 1.91
During the past 12 months, the average Revenue per Share Growth Rate of Knight Therapeutics was 39.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 20.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 24.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 85.00% per year.
During the past 13 years, Knight Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 193.20% per year. The lowest was 20.90% per year. And the median was 96.10% per year.
Back to Basics: PS Ratio
Knight Therapeutics (FRA:04K) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Knight Therapeutics PS Ratio Related Terms
Knight Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Knight Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Knight Therapeutics PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Knight Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Knight Therapeutics's Share Price of today is €6.20. Knight Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Knight Therapeutics (FRA:04K) has a PS Ratio of 1.93 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Knight Therapeutics and its competitors. This is 42% below median its historical median of 3.31. Over the past decade, Knight Therapeutics' PS Ratio has ranged from 1.28 to 400.42. According to the industry distribution chart, Knight Therapeutics ranks #421 out of 955 companies in the Drug Manufacturers industry, placing it in the top 44.1%.
Is Knight Therapeutics' PS Ratio too high?
Knight Therapeutics' current PS Ratio of 1.93 is 42% below median its 10-year median of 3.31. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 400.42. The Drug Manufacturers industry median PS Ratio is 2.30. Knight Therapeutics' value of 1.93 is 16.1% below this industry median. Based on the distribution chart, Knight Therapeutics ranks #421 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #421 out of 955 companies for PS Ratio. This puts Knight Therapeutics in the upper half of its industry. The industry median PS Ratio is 2.30. Knight Therapeutics' value of 1.93 is 16.1% below this benchmark. Historically, Knight Therapeutics' own PS Ratio has ranged from 1.28 to 400.42 over the past decade. While the company's 10-year median is 3.31 vs. the industry median of 2.30, Knight Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current PS Ratio of 1.93 is 16.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current PS Ratio is 1.93, which is 42% below median its own 10-year median of 3.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current PS Ratio of 1.93. The stock's GF Value™ is €5.47, compared to a current price of €6.20 — trading 13.3% above its estimated fair value. The current PS Ratio is 1.93, which is 42% below median its 10-year median of 3.31 and 16.1% below the Drug Manufacturers industry median of 2.30. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current PS Ratio is 1.93 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Knight Therapeutics (FRA:04K) Overvalued in 2026?
Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued.
The current stock price of €6.20 is trading 13.3% above its estimated GF Value™ of €5.47.
Key valuation signals for FRA:04K:
PS Ratio: 1.93 (42% below median its 10-year median of 3.31)
GF Value™: €5.47 vs. price of €6.20 (13.3% above fair value)
Industry Position: 16.1% below the Drug Manufacturers median (#421 of 955)
No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score
Get the complete analysis for FRA:04K
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:04K has been successfully added to your 
